Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
<b>Background</b>: Extracellular vesicles (EVs) can carry pathological cargo, contributing to disease progression. The enzyme neutral sphingomyelinase 2 (nSMase2) plays a critical role in EV biogenesis, making it a promising therapeutic target. Our lab previously identified a potent and...
Saved in:
Main Authors: | Arina Ranjit, Chae Bin Lee, Lukáš Tenora, Vijaya Saradhi Mettu, Arindom Pal, Jesse Alt, Barbara S. Slusher, Rana Rais |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/1/20 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01) -
Development and Application of Physiologically-Based Pharmacokinetic Model to Predict Systemic and Organ Exposure of Colorectal Cancer Drugs
by: Sara Peribañez-Dominguez, et al.
Published: (2025-01-01) -
Population Pharmacokinetic of Epidural Sufentanil in Labouring Women: A Multicentric, Prospective, Observational Study
by: Nie Y, et al.
Published: (2025-02-01) -
A comprehensive review on the plant sources, pharmacological activities and pharmacokinetic characteristics of Syringaresinol
by: Lei Zhang, et al.
Published: (2025-02-01) -
Biological Properties, Bioactive Constituents, and Pharmacokinetics of Some Capsicum spp. and Capsaicinoids
by: Gaber, El-Saber Batiha, et al.
Published: (2023)